Aller au contenu principal
Accès ouvert déclaré 2026 article

Suspected retention of magnesium oxide tablets during co-administration with recovery K5, a concentrated oral enteral nutrition formula, supported by in vitro disintegration testing

0Citations signalées — pas une note de qualité
4Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Background Concentrated oral enteral nutrition (EN) formulas are used when adequate energy intake is required despite limited feeding volume, but their compatibility with tablets has not been fully evaluated. We observed computed tomography (CT) findings suggestive of gastrointestinal retention of magnesium oxide (MgO) tablets in an older inpatient receiving concentrated EN and performed an exploratory in vitro disintegration study. Methods Clinical medication, nutrition, and CT data were reviewed retrospectively. The CT attenuation and diameter of intraluminal tablet-like structures were compared with those of an intact MgO tablet scanned in water. For in vitro testing, MgO tablets were evaluated using Japanese Pharmacopoeia-based disintegration testing in purified water, simulated gastric fluid, and simulated intestinal fluid, with or without 30-min pre-exposure to Recovery K5, a concentrated oral EN formula. Direct disintegration in Recovery K5 was also examined as a worst-case condition. Results were summarized descriptively. Results CT showed three discrete high-attenuation intraluminal structures measuring 9.0–9.4 mm and 501–880 HU, findings compatible with suspected undisintegrated MgO tablets. Without pre-exposure, MgO tablets disintegrated within 8–10 s. After pre-exposure to Recovery K5, mean disintegration times increased to 338.5–422.2 s. In Recovery K5 itself, tablets remained incompletely disintegrated beyond 10,020 s. Conclusions This brief report does not establish definitive causality, but it identifies a clinically relevant signal supported by in vitro evidence. These findings support pharmacist-led review of the actual administration sequence, water volume, and dosage-form selection when MgO tablets are administered concomitantly with Recovery K5, a concentrated oral EN formula.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Suspected retention of magnesium oxide tablets during co-administration with recovery K5, a concentrated oral enteral nutrition formula, supported by in vitro disintegration testing
Date Crossref
03/09/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Pharmacy and Medical PracticesClinical Nutrition and GastroenterologyDysphagia Assessment and Management

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.